Disc Medicine: Seeking Iron Balance via Hepcidin

Disc debuts with a $50 million series A round and a pair of hepcidin modulators to rebalance iron in hematological disorders

Disc debuted Tuesday with a $50 million series A round and a pair of hepcidin modulators aimed at carving a place in hematological disorders, alongside a host of disease-modifying therapies that are much closer to market.

Novo Holdings A/S led the round with participation by Access Biotechnology and founding investing Atlas Venture, which seeded Cambridge, Mass.-based Disc Medicine Inc. with $5 million in October 2017.

In addition to the financing, Disc revealed Tuesday a

Read the full 735 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE